- Eli Lilly (LLY, Financial) and Novo Nordisk remain resilient amid potential new pharmaceutical tariffs.
- Analysts foresee a 14.87% potential upside for Eli Lilly, with price targets ranging from $800.00 to $1,190.00.
- GuruFocus estimates suggest a 27.36% upside for Eli Lilly, indicating it may be undervalued.
Eli Lilly (LLY) and Novo Nordisk are strategically positioned to endure the potential challenges posed by new pharmaceutical tariffs, thanks to their strong market dominance. While these tariffs threaten to increase U.S. drug costs significantly, Eli Lilly's robust obesity treatment portfolio enhances its growth prospects.
Wall Street Analysts Forecast
Wall Street analysts have set a diverse range of one-year price targets for Eli Lilly and Co (LLY, Financial). With projections from 25 analysts, the average target price stands at $1,016.05. This includes a high estimate of $1,190.00 and a low of $800.00, suggesting a potential upside of 14.87% from the current market price of $884.54. For more in-depth analysis, visit the Eli Lilly and Co (LLY) Forecast page.
Additionally, the consensus recommendation from 29 brokerage firms currently places Eli Lilly and Co (LLY, Financial) at an average rating of 1.9, aligning with an "Outperform" status. This rating operates on a scale from 1 to 5, where 1 signifies a Strong Buy and 5 indicates a Sell.
GuruFocus provides further insights with an estimated GF Value for Eli Lilly and Co (LLY, Financial) over the next year at $1126.52. This implies a significant upside of 27.36% from its present trading value of $884.54. The GF Value represents GuruFocus' calculated fair value based on the stock's historical trading multiples, past business growth, and anticipated future performance. For a comprehensive overview, consult the Eli Lilly and Co (LLY) Summary page.
